Novel E3 Ligase Ligand Screening Services

Q: How do you confirm that target degradation is driven specifically by the recruited novel E3 ligase?

We validate mechanism-of-action via CRISPR/Cas9 genetic knockouts, RNAi-mediated knockdowns, proteasome/cullin pathway inhibition, and competitive E3 ligand rescue experiments to demonstrate that target clearance relies strictly on the targeted novel E3 ligase.

Background Service Package Workflow Why Us? FAQRelated Services

At Creative Biolabs, we provide comprehensive Novel E3 Ligase Ligand Screening Services to propel the next generation of targeted protein degradation (TPD) therapeutics. While traditional degradation technologies heavily rely on a limited set of conventional E3 ligases (such as CRBN and VHL), expanding the accessible E3 ligase repertoire is paramount to overcoming drug resistance, achieving tissue-selective degradation, and targeting previously "undruggable" disease drivers. Leveraging our advanced biophysical screening technologies, structural biology engine, and extensive chemical libraries, we offer tailored screening platforms for a wide spectrum of emerging E3 ligases.

Background of Novel E3 Ligase Ligand in Protein Degradation

The human genome encodes over 600 E3 ubiquitin ligases, yet the vast majority of heterobifunctional degraders in clinical development recruit only CRBN or VHL. Relying on such a narrow subset introduces significant therapeutic vulnerabilities, including acquired resistance via ligase mutations or downregulation, lack of tissue specificity, and limited efficacy against certain cellular compartments.

Co-opting novel, alternative E3 ligases through Creative Biolabs' screening platform offers transformative pharmacological advantages:

Overcoming Resistance: Bypasses genomic loss-of-function alterations, point mutations, or epigenetic silencing associated with CRBN and VHL.
Tissue & Cellular Selectivity: Taps into tissue-restricted or compartment-specific E3 ligases (e.g., muscle-enriched or nuclear-localized ligases) to restrict target clearance to disease-relevant tissues and minimize systemic toxicities.
Structural Diversity: Accesses distinct binding modes—including non-covalent hydrophobic pockets, electrophilic covalent cysteine targets, and degron-recognition cavities—to expand chemical space and optimize ternary complex formation.

Structure of protein degradation. (Creative Biolabs AI) Fig.1 Ternary complex structure in protein degradation.

Comprehensive Novel E3 Ligase Screening Portfolio

At Creative Biolabs, our service goes beyond routine high-throughput screening. We provide an end-to-end, milestone-driven discovery engine designed to overcome the structural and chemical challenges of hijacking the CUL3-KEAP1 machinery. By partnering with us, clients can seamlessly advance their degrader pipeline across key project stages:

KEAP1 based Protein Degrader Ligand Screening

KEAP1 functions as a substrate recognition adaptor for the CRL3^KEAP1 E3 ubiquitin ligase complex. In targeted protein degradation, co-opting KEAP1 via its Kelch domain binding pocket allows for potent, highly efficient ubiquitination of target proteins. KEAP1 provides a strategic advantage due to its well-defined ligandable pocket and preferential liver/kidney tissue expression, making it an ideal engine for tissue-targeted protein degradation.

RNF114 based Protein Degrader Ligand Screening

RNF114 is a RING-type E3 ubiquitin ligase that directly transfers ubiquitin to target substrates. In TPD, RNF114 possesses reactive, ligandable cysteine residues (e.g., Cys8) amenable to targeted covalent ligand recruitment. Co-opting RNF114 enables rapid, irreversible ligand engagement and highly potent cellular target degradation across various cancer cell lines.

KLHL22 based Protein Degrader Ligand Screening

KLHL22 serves as a substrate receptor within the Cullin 3-RING E3 complex CRL3^KLHL22, mediating the ubiquitination and degradation of key metabolic and cell-cycle regulators (e.g., DEPDC5). Engaging KLHL22's Kelch domain cavity provides an attractive pathway to construct heterobifunctional degraders that exploit active metabolic machinery for targeted substrate clearance.

FBXO22 based Protein Degrader Ligand Screening

FBXO22 operates as an F-box substrate recognition adaptor in the CRL1^FBXO22 (SKP1-CUL1-F-box) complex, specializing in nuclear substrate degradation (such as methylated histone demethylases and transcription factors). Co-opting FBXO22 enables targeted degradation of nuclear-localized protein targets that are often resistant to cytoplasmic E3 machinery.

TRIM21 based Protein Degrader Ligand Screening

TRIM21 is a cytosolic RING-type E3 ligase with exceptionally high ubiquitin transfer catalytic efficiency upon auto-assembly. In targeted proteolysis, engaging TRIM21 harnesses its potent intracellular antibody-binding (PRYSPRY) pathway or small-molecule binding sites, triggering rapid, complete proteasomal clearance of cytosolic and viral protein targets.

RNF4 based Protein Degrader Ligand Screening

RNF4 is a SUMO-targeted ubiquitin ligase (STUbL) containing RING catalytic domains that selectively polyubiquitinate sumoylated or nuclear scaffold substrates. Utilizing RNF4 in degrader development provides a targeted approach to clearing chromatin-associated protein complexes, transcription factors, and nuclear inclusions.

AhR based Protein Degrader Ligand Screening

The Aryl Hydrocarbon Receptor (AhR) acts as a ligand-inducible transcription factor that, upon ligand binding, functions as an E3 ubiquitin ligase component to promote substrate degradation. Screening AhR recruiters allows researchers to exploit ligand-dependent conditional activation for controlled, inducible targeted protein degradation.

FEM1B based Protein Degrader Ligand Screening

FEM1B is an V-degron recognition adaptor for Cullin 2 CRL2^FEM1B complexes, recognizing specific N-terminal or internal degrons under physiological stress. Co-opting FEM1B provides a robust platform to develop degrader molecules that exploit CUL2-dependent machinery for high-depth substrate depletion.

DCAF based Protein Degrader Ligand Screening

DDB1- and CUL4-associated factors (DCAFs, including DCAF1, DCAF11, and DCAF15) function as substrate recognition receptors for CRL4^DCAF complexes. The structural diversity of WD40-repeat domains within the DCAF family offers a broad spectrum of ligandable pockets, unlocking versatile choices for tissue- and cell-lineage-specific degradation architectures.

IAP based Protein Degrader Ligand Screening

Inhibitor of Apoptosis Proteins (cIAP1, cIAP2, XIAP) possess RING domains capable of driving rapid autoubiquitination and substrate proteolysis. Screening BIR-domain-binding ligands (such as SMAC mimetics) allows for the assembly of potent degraders that recruit IAP ligases to induce target degradation while simultaneously modulating survival signaling pathways.

KLHDC2 based Protein Degrader Ligand Screening

KLHDC2 serves as a substrate adaptor for CRL2^KLHDC2 complexes, recognizing exposed C-terminal diglycine (-Gly-Gly) degrons. Co-opting KLHDC2 via its central Kelch domain propeller cavity provides low-nanomolar binding affinity and highly efficient C-degron-mediated targeted clearance of refractory proteins.

GID4 based Protein Degrader Ligand Screening

GID4 is the dedicated substrate recognition subunit of the human CTLH Cullin-RING E3 ligase complex, targeting N-terminal Proline (Pro/N-degrons). GID4 features a deep, narrow, hydrophobic β-barrel pocket, making it an exceptional structural template for recruiting ligands to clear both nuclear and cytosolic targets.

KLHL41 based Protein Degrader Ligand Screening

KLHL41 (KBTBD10) is a substrate-recognition adaptor for Cullin 3 CRL3^KLHL41. Uniquely, KLHL41 exhibits restricted expression enriched in skeletal muscle tissue. Recruitment of KLHL41 allows for tissue-selective protein degradation, effectively restricting substrate clearance to muscle tissues while sparing non-target healthy organs.

Workflow of Novel E3 Ligase Ligand Screening

Creative Biolabs delivers a fully integrated, multi-phase operational workflow that transitions projects seamlessly from initial hit identification to full cellular degradation confirmation.

Workflow of Novel E3 Ligase Ligand Screening. (Creative Biolabs Original)

Stage 1

High-Throughput Primary Screening

Screening diverse chemical libraries, DNA-Encoded Libraries (DEL), fragment sets, or targeted peptide/peptidomimetic collections via Fluorescence Polarization (FP), TR-FRET, or Surface Plasmon Resonance (SPR).

Stage 2

Biophysical Profiling & Counter-Screening

Quantifying precise binding affinities (K_D) and kinetic parameters using SPR, Isothermal Titration Calorimetry (ITC), or MicroScale Thermophoresis (MST), alongside counter-screening against off-target E3 family members.

Stage 3

Co-Crystallography & Vector Mapping

Solving high-resolution X-ray or Cryo-EM structures of candidate ligands bound to the target E3 ligase to establish precise exit vectors for linker attachment.

Stage 4

Bifunctional Synthesis & Cellular Readouts

Conjugating optimized E3 ligands to target-binding moieties to build functional degraders, followed by cellular validation (Western blot, quantitative mass-spectrometry proteomics) and mechanism-of-action testing.

Advantages of Our Services

As a recognized pioneer in targeted protein degradation technologies, Creative Biolabs combines advanced screening infrastructures with extensive drug discovery expertise to accelerate novel E3 ligase ligand discovery. Our platform provides clients with unparalleled capabilities to streamline early-stage degrader development through the following key strengths:

Broadest Novel E3 Portfolio

Pre-validated assays and deep structural expertise across an unmatched panel of Cullin-RING, RING, HECT, and RBR E3 ligases.

In-House Structural Biology Engine

Co-crystallization and Cryo-EM capabilities providing high-resolution atomic structures to drive structure-based drug design (SBDD).

Advanced Screening Modalities

Seamless integration of DEL technology, targeted covalent chemoproteomics, and high-throughput biophysical profiling platforms.

End-to-End Execution

Comprehensive support bridging hit discovery, biophysical kinetic profiling, linker chemistry optimization, and cellular degradation kinetics.

Frequently Asked Questions

Q1: Why should I explore novel E3 ligases instead of established options like CRBN or VHL?

A: Conventional E3 ligases are susceptible to acquired resistance mechanisms through point mutations or downregulations in clinical settings. Novel E3 ligases provide alternative degradation pathways, access to tissue-restricted or compartment-specific expression profiles, and distinct binding geometries capable of clearing targets refractory to standard ligases.

Q2: Can Creative Biolabs screen for both covalent and non-covalent novel E3 recruiters?

A: Yes. We offer electrophilic small-molecule screening platforms targeting reactive nucleophilic residues (e.g., cysteine, lysine) for targeted covalent ligand discovery (e.g., RNF114, KEAP1), as well as reversible small-molecule, fragment, and peptidomimetic platforms for non-covalent pockets.

Q3: How do you confirm that target degradation is driven specifically by the recruited novel E3 ligase?

A: We validate mechanism-of-action via CRISPR/Cas9 genetic knockouts, RNAi-mediated knockdowns, proteasome/cullin pathway inhibition, and competitive E3 ligand rescue experiments to demonstrate that target clearance relies strictly on the targeted novel E3 ligase.

Whether your objective is to overcome clinical resistance, achieve precise tissue-selective degradation, or unlock previously refractory therapeutic targets, our team is equipped to tailor an optimal novel E3 ligase ligand screening strategy to meet your exact scientific goals. Contact our expert scientific team today to discuss your project requirements or to request a custom project proposal.

Contact Our Team for More Information and to Discuss Your Project →

Related Services

Solutions

Online Inquiry